Novo Nordisk's acquisition of US-based biotech firm Dicerna for USD 3.3bn has been hit by a legal aftermath. Shareholders in Dicerna have filed separate suits against the firm and its board of directors, alleging violations of the US Securities Exchange Act, reports Law Street Media.
On Nov. 18, Novo Nordisk and Dicerna announced the merger deal, and on Nov. 24, Dicerna's board recommended the deal to its shareholders. Plaintiffs Laurie Volpe and Matthew Hopkins say the provided information was "materially incomplete and misleading".
More from MedWatch
Experiences from Danish climate partnerships are among the tools that can be leveraged when Novo Nordisk CEO Lars Fruergaard begins stepping up efforts in the life science sector’s central organs in Brussels. ”I’ve been fired up by the intimacy and shared vision we could see in Denmark,” he tells MedWatch.